Company Overview and News
For a few days, it looked like the market might get back into a “risk on” mood again, favoring growth names regardless of their frothy valuations, at the expense of consumer-oriented stocks regardless of their all-weather reliability.
NWL WHR EPC FBHS AAPL PKG CRI MHK HBI BC
Seeking investments that are fairly valued today is like looking for a needle in a haystack. After a 10-year bull market, there are slim pickings in this frothy market. It reminds me of 1998, when I was looking for value stocks during the dot com boom. Everything was richly valued.
0941 PRU MAT CHLKF CHL PRH TEF PFK HBI PJH
The Nasdaq Composite, Nasdaq 100, small cap Russell 2000, Value Line Arithmetic and the NYSE Arca Biotechnology were among U.S. indices trading to all-time highs during Wednesday's session. In the real world, there is escalating risk of a destabilizing global trade war. The Shanghai Composite sank 4.4% this week to two-year lows. It was another week of instability for emerging market equities, bonds and currencies - especially in Asia.
LOW SYMC SIG AKRX KMX CHKVP UAA RL TWX CHKVZ SAM ASNA GM.WS.A TWTR GM.WS.B GM.WS.C CHK.PRD RCII CMCSK TWC FOSL NDAQ NTXFF CHK FL GM.WSB BA HBI CCV CONN NFLX AMD CCZ NTXFY CHKDH CHKDG FMCKI FMCKJ CHKDJ KR CHKDP BOE AAPL KSS SWN GM CKRGZ FMCCO FMCCP FMCCM FMCCN CMCSA TRIP FMCCI FMCCJ CVNA M FMCCG FMCKO NYTAB FMCKP FMCKM IWM FMCKN FMCKK FMCKL CHKWZ SIG W UA LHHMQ FMCC MU CCV.CL CHK.WI TSLA KN MNK GNW FIVE FMCCS FMCCT
Shares of Hanesbrands Inc. (HBI - Free Report) have rallied 25% over the past month, outperforming the industry’s gain of 15%. The company, which has been gaining from its international strength, strong online business and impressive organic sales, has rallied 19.1% since the release of first-quarter 2018 results.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PANDY GOOS ADDDF ADDYY PPRUY RL PNDZF ROST PNDZY PVH KER LULU PPRUF HBI
Hanesbrands Inc. (HBI) has been notable over the past couple of months for a couple of reasons: first, the news that its Champion brand is considering more brick-and-mortar stores in the face of declining foot traffic; and second, the 3.17% rise in its share price on May 15, with 8.02 million shares trading that day. This notability naturally draws one to consider Hanesbrands as a prospective investment.
PBG HBI PFBDY PBG
Entravision, Entercom, and Viacom topped the sector by price target upsides, while Barnes, GameStop, and L Brands led as top yield Consumer Cyclical sector favorites per estimates collected 5/14/18.
EVC TSQ TAX M ETM.WI LB MDP FUN GME ETM CSS SIX ESCA GM.WS.A GM.WS.B GM.WS.C BKS GM GM.WSB HBI TUP
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to HBI / Hanesbrands, Inc. on message board site Silicon Investor.
|HBIO Harvard Bioscience||HOMEBASE (HBI)|
as of ET